Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Announces Earnings Results

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) released its quarterly earnings data on Monday, August 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.04, Zacks reports. The business had revenue of $5.55 billion during the quarter, compared to analyst estimates of $5.48 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.83% and a return on equity of 9.28%.

Fresenius Medical Care AG & Co. KGaA Stock Up 0.5%

FMS traded up $0.10 during trading on Friday, reaching $22.34. The company had a trading volume of 249,088 shares, compared to its average volume of 684,048. The business’s fifty day moving average price is $23.82 and its 200 day moving average price is $23.01. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.07 and a quick ratio of 0.75. Fresenius Medical Care AG & Co. KGaA has a 12 month low of $20.02 and a 12 month high of $27.64. The company has a market cap of $12.00 billion, a P/E ratio of 11.57, a PEG ratio of 4.14 and a beta of 0.76.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Morgan Stanley boosted its position in Fresenius Medical Care AG & Co. KGaA by 47.2% during the fourth quarter. Morgan Stanley now owns 2,939,839 shares of the company’s stock valued at $70,027,000 after purchasing an additional 942,497 shares during the last quarter. Integral Health Asset Management LLC grew its position in shares of Fresenius Medical Care AG & Co. KGaA by 44.4% in the 4th quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock valued at $15,483,000 after acquiring an additional 200,000 shares during the period. Bank of America Corp DE grew its position in shares of Fresenius Medical Care AG & Co. KGaA by 279.7% in the 2nd quarter. Bank of America Corp DE now owns 337,316 shares of the company’s stock valued at $9,637,000 after acquiring an additional 248,477 shares during the period. Millennium Management LLC increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 2.8% during the 3rd quarter. Millennium Management LLC now owns 317,109 shares of the company’s stock worth $8,349,000 after purchasing an additional 8,719 shares during the last quarter. Finally, Raymond James Financial Inc. raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 1.5% in the 3rd quarter. Raymond James Financial Inc. now owns 282,074 shares of the company’s stock valued at $7,427,000 after purchasing an additional 4,079 shares during the period. 8.37% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

FMS has been the subject of several research reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, August 4th. Zacks Research upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. BNP Paribas Exane cut shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating and set a $19.90 target price on the stock. in a research note on Tuesday, July 28th. Truist Financial set a $25.00 price target on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Wednesday, August 5th. Finally, Sanford C. Bernstein boosted their price target on Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the company a “market perform” rating in a research note on Thursday, August 6th. Six investment analysts have rated the stock with a Hold rating and five have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus target price of $23.57.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on kidney disease and dialysis services. The company provides hemodialysis and peritoneal dialysis treatments through a global network of outpatient dialysis clinics and supports patients with related care and medical services.

In addition to operating dialysis centers, Fresenius Medical Care develops and manufactures products used in renal care. Its portfolio includes dialysis machines, dialyzers, bloodlines, concentrates, solutions, pharmaceuticals and other disposable supplies.